assignment
Not Recruiting

Phase II Randomized Study of RO7121661 and RO7247669 Versus Nivolumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Trial ID
2024-511403-41-00
Protocol
BP42772

Register record, history and transparency: CTIS.eu

Trial statistics

science
1
test molecule
location_city
13
research sites
public
6
countries
medical_information
1
disease
person_search
14
investigators
handshake
11
vendors

Diseases & Conditions

Oesophageal carcinoma

Objectives

The primary objective of this study is to evaluate the **efficacy** of RO7247669 compared with nivolumab based on overall survival in participants with advanced or metastatic squamous cell carcinoma of the esophagus. This is clinically relevant as it aims to determine whether RO7247669 can provide a survival benefit over the current standard treatment, nivolumab, potentially offering a new therapeutic option for this patient population.

Secondary objectives include:

  • Evaluating the safety and tolerability of RO7121661 and RO7247669 compared with nivolumab.
  • Assessing the efficacy of RO7247669 compared with nivolumab based on objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), and the proportion of participants reporting clinically meaningful improvement in global health status/quality of life, emotional functioning, social functioning, and dysphagia.
  • Investigating the pharmacokinetics (PK) of RO7247669 and nivolumab.
  • Evaluating the immune response after administration of RO7247669 and nivolumab.
  • Assessing treatment-induced pharmacodynamic (PD) changes (PD Biomarkers) in peripheral blood and tumor microenvironment.
  • Assessing baseline characteristics in the tumor microenvironment as predictive biomarkers of response.

Participants

The clinical trial involves a total of **151 participants** diagnosed with **advanced or metastatic squamous cell carcinoma of the esophagus**. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. Participants were selected based on specific criteria, including having a radiologically measurable disease according to RECIST v1.1, an ECOG Performance Status of 0-1, and adequate hematological, liver, and renal function. The trial also considers individuals who have resolved adverse events from prior treatments to a manageable level. The population includes a vulnerable group, indicating a careful selection process to ensure safety and efficacy assessments. Lifestyle factors such as diet and physical activity were not specified in the available data.

Plans and Procedures

The clinical trial is designed as a **randomized**, **blinded**, active-controlled, Phase II study to evaluate the efficacy of RO7247669 compared with nivolumab in participants with advanced or metastatic **squamous cell carcinoma of the esophagus**. The trial involves three arms, including the investigational drugs RO7121661 and RO7247669, both of which are bispecific antibodies, and a control arm with nivolumab. The primary objective is to assess overall survival, while secondary endpoints include the frequency and severity of adverse events, objective response rate, disease control rate, duration of response, progression-free survival, and quality of life improvements, among others. The trial is expected to conclude by June 30, 2025, with recruitment having commenced on August 10, 2021.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as radiologically measurable disease, ECOG Performance Status of 0-1, and adequate hematological, liver, and renal function. Follow-up visits will be scheduled to monitor treatment response and safety, with assessments including imaging studies, laboratory tests, and quality of life questionnaires. The end-of-study visit will occur after the completion of the treatment period or upon early termination. The expected length of participant involvement will vary depending on individual response and progression, but it is anticipated to last until the study's conclusion or until disease progression or unacceptable toxicity occurs. Conditions that may lead to early termination from the study include significant adverse events or withdrawal of consent by the participant.

Treatment

The clinical trial involves the evaluation of **RO7247669**, a bispecific antibody targeting PD1 and LAG3, developed by F. Hoffmann-La Roche Ltd. The pharmaceutical form, dosage, route, and frequency of administration for RO7247669 are not specified in the provided data. This investigational product is not a pediatric formulation and is not classified as an orphan drug. The active substance in RO7247669 is of protein origin, specifically categorized as "Protein - Other." The trial aims to assess the efficacy of RO7247669 in comparison to nivolumab, focusing on overall survival in participants with advanced or metastatic squamous cell carcinoma of the esophagus.

In addition to the experimental treatment, the study includes a comparator treatment with **nivolumab**, a standard-of-care therapy for certain types of cancer. Nivolumab is a well-established immune checkpoint inhibitor that targets the PD-1 receptor, enhancing the body's immune response against cancer cells. The specific details regarding the pharmaceutical form, dosage, route, and frequency of administration for nivolumab are not provided in the data. The trial is designed as a 3-arm, randomized, blinded, active-controlled, Phase II study, ensuring a rigorous comparison between the investigational product and the standard treatment.

Efficacy

The efficacy of the investigational product RO7247669 will be assessed in a clinical trial involving participants with advanced or metastatic **Squamous Cell Carcinoma of the Esophagus**. The primary endpoint for evaluating efficacy is overall survival, which will be compared between RO7247669 and the active control, nivolumab. Secondary endpoints include a range of measures such as the frequency and severity of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0), objective response rate (ORR) defined as the proportion of participants with a complete or partial response according to RECIST v1.1, and disease control rate (DCR) which includes ORR plus stable disease rate.

Additional secondary endpoints involve duration of response (DoR), progression-free survival (PFS), and patient-reported outcomes related to quality of life improvements measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ-C30, QLQ-IL97, and QLQ-OES-18). Serum concentrations of RO7121661, RO7247669, and nivolumab will be monitored, along with the incidence and titer of anti-drug antibodies (ADAs) against these agents. Changes in T cell subsets and tumor microenvironment markers such as CD8 T cell infiltration and proliferation will also be evaluated. These efficacy parameters will be collected and analyzed at specified timepoints throughout the trial to determine the therapeutic impact of RO7247669 compared to the control treatment.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

  • Radiologically measurable disease according to Response evaluation criteria in solid tumors version 1.1 (RECIST v1.1). Previously irradiated lesions should not be counted as target lesions unless clearly progressed after the radiotherapy
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
  • AEs from any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to Grade <=1, except alopecia (any grade), vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 peripheral neuropathy
  • Adequate hematological function
  • Adequate liver function
  • Adequate renal function
cancel

Exclusion Criteria

  • Pregnancy, lactation, or breastfeeding
  • Patients with significant malnutrition. Patients whose nutrition has been well controlled for ≥28 days prior to randomization may be enrolled
  • Active or history of carcinomatous meningitis/leptomeningeal disease
  • Uncontrolled tumor-related pain. Participants requiring pain medication must be on a stable regimen at study entry.
  • Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent.
  • Known clinically significant liver disease, including alcoholic hepatitis, cirrhosis, and inherited liver disease

Trial Status by Country

Country Status Start of Recruitment Planned Patients
Denmark DenmarkNot Recruiting10 Aug 202114
France FranceNot Recruiting10 Aug 202124
Hungary HungaryNot Recruiting10 Aug 20212
Italy ItalyNot Recruiting10 Aug 202115
Poland PolandNot Recruiting10 Aug 20219
Spain SpainNot Recruiting10 Aug 202115

Sites & Investigators

Conditions Studied in This Trial